Biography for Suzanne Elvidge
Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at firstname.lastname@example.org. Follow @suzannewriter on Twitter.
- Contact Suzanne
- Follow Suzanne on Google+
Articles by Suzanne Elvidge
What's the focus of Alzheimer's disease vaccine research? Dr. Daniel Chain, Intellect Neurosciences' chairman and CEO, gave FierceVaccines his thoughts.
GAVI Alliance could be closer to HPV vax deal
GAVI could be nearing a price deal with vaccine rivals GlaxoSmithKline and Merck for HPV vaccines Gardasil and Cervarix in the developing world.
Some childhood brain cancers don't respond well to treatment and the outcomes are not good for the patient.
A study has shown that measles-containing vaccines such as measles-mumps-rubella vaccine (MMR), with or without the varicella vaccine (V), do not increase the risk of febrile seizures.
Part of the success of some cancers is that they can avoid an immune response, and this can also cut the response to vaccines. Immunovaccine is developing a comeback to this--suppress the suppression.
Belagenpumatucel-L (NovaRx's Lucanix) is a cell-based therapeutic vaccine that is being studied in non-small cell lung cancer (NSCLC).
A team at the University of Saskatchewan, along with VIDO-InterVac, is developing a nasal vaccine against respiratory syncytial virus that shows promise in the lab.
At the Frontiers in CardioVascular Biology 2012 meeting, professor Jan Nilsson suggested that vaccines and monoclonal antibodies could be used to treat atherosclerosis.
Study: No benefit for Merck's zoster booster
A paper presented to the American Academy of Dermatology looked at the effectiveness of a booster shot of a VZV vaccine.
Merck's Gardasil is used to protect women against HPV infection, but it may help some women already infected.